NGNE vs PKOH Comparison

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

Park-Ohio Holdings Corp is a diversified international company offering its clients supply chain management outsourcing services, capital equipment used on their production lines, and manufactured components used to assemble their products. The company operates through three reportable segments: Supply Technologies, Assembly Components, and Engineered Products. Maximum revenue is generated from the Supply Technologies segment, which is mainly engaged in sourcing, planning, and procurement of several production components, including fasteners, pins, nuts, bolts, valves, hoses, wire harnesses, clamps and fittings, etc. Geographically, the company generates maximum revenue from its business in the United States, followed by Europe, Asia, Mexico, Canada, and other regions.